A drug that clears out aging skin cells passes its first human safety test
A biotech company targeting so-called zombie cells — cells that stop dividing but refuse to die and instead damage surrounding tissue — has shown for the first time that its approach appears…
Rubedo Life Sciences recently announced preliminary results from a Phase 1 clinical trial of RLS-1496, tested in patients with plaque psoriasis, atopic dermatitis, and photo-aged skin. The study was double-blind and placebo-controlled, the gold standard for early clinical research, and involved escalating doses to assess both safety and early signs of efficacy. The trial was conducted at a single center in the European Union.
The cells targeted by RLS-1496 are known as senescent cells. As the body ages, these cells accumulate in tissues and release inflammatory signals that damage healthy neighbors. This process — sometimes called the senescence-associated secretory phenotype, or SASP — is widely considered one of the drivers of aging-related disease. Drugs designed to eliminate these cells are called senolytics, and they have attracted intense scientific and commercial interest over the past decade.
Why skin makes sense as a testing ground
Targeting skin conditions as the entry point for a senolytic is a deliberate choice. The skin is directly observable, easy to biopsy, and rich in senescent cells, particularly after chronic sun exposure. Inflammatory skin diseases like psoriasis and eczema also involve the kind of low-grade, persistent inflammation that senescent cells are thought to fuel. A measurable effect here would provide meaningful evidence that the mechanism works in living humans — not just in mice, where senolytics have repeatedly shown dramatic results.
Rubedo uses artificial intelligence to identify molecular signatures that distinguish senescent cells from healthy ones. The idea is to build drugs that are more precise than first-generation senolytics, some of which had broad effects on non-target cells. RLS-1496 is designed around a specific protein target that is elevated in aged skin cells.
Promising, but the hard questions remain
The preliminary results have been described as positive, but Rubedo has not yet published detailed efficacy data in a peer-reviewed journal, making independent scrutiny difficult at this stage. Phase 1 trials are primarily designed to establish safety and dosing, not to prove that a drug works. The real test — whether it outperforms placebo in a larger, longer trial — lies ahead.
Still, this represents a meaningful step for the senolytic field. Other compounds, including dasatinib and quercetin, are already in human trials, but RLS-1496 is among the first to be developed specifically for skin using an AI-guided design process. Whether that approach delivers a real advantage over earlier methods remains to be seen. The history of longevity research is full of results that looked compelling early and faded under harder scrutiny.